Everest Medicines

News

09 2020/12

Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy^™ (sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
02 2020/12

Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy
10 2020/11

Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
03 2020/11

Everest Medicines Announces First Patient Dosed in its Phase 2b Registration Clinical Trial of Trodelvy^™ (sacituzumab govitecan) for Metastatic Triple-Negative Breast Cancer in China
02 2020/11

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Trodelvy^™ for Metastatic Breast Cancer in China
08 2020/10

Everest Medicines Announces the Offer Price and Allotment Results of the Global Offering
25 2020/09

Everest Medicines Announced Its Global Offering and Proposed Listing on the Stock Exchange of Hong Kong
15 2020/09

Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China
08 2020/09

Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China
28 2020/08

Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava^™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China
07 2020/08

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors
22 2020/06

Everest Medicines Announces Positive Results of In Vitro Study of Xerava^™ (eravacycline) Against Human Mycoplasmas

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号